依據歐盟施行的個人資料保護法，我們致力於保護您的個人資料並提供您對個人資料的掌握。 我們已更新並將定期更新我們的隱私權政策，以遵循該個人資料保護法。請您參照我們最新版的 隱私權聲明。
本網站使用cookies以提供更好的瀏覽體驗。如需了解更多關於本網站如何使用cookies 請按 這裏。
最新消息
Latest News
品牌新聞
19.Jan.2023
母嬰益生菌 HN001™
Lactobacillus Rhamnosus HN001™
母嬰益生菌
( 一 ) 菌種特徵 :
1. 格蘭氏陽性菌
2. 兼性厭氧、不生芽孢
3. 安全可食用性
乳桿菌被作為食品食用具有多年歷史，鼠李糖乳桿菌HN001™被列入歐盟食品安全局(EFSA)的安全資格認定列表中。
並透過急性與慢性體外實驗測試安全性，其中一項實驗結果顯示，每日餵食鼠李糖乳桿菌 HN001™餵食給小鼠後並未
產生健康之不利影響。
4. 可耐胃酸及膽鹽
根據體外試驗的結果顯示，鼠李糖乳桿菌HN001™具有良好對抗胃酸以及膽鹽能力。
5. 良好附著腸道上皮組織能力
根據不同菌株對人體腸道上皮細胞的黏附指數之實驗結果顯示，鼠李糖乳桿菌HN001™相較於其他實驗菌株在HT-29、
Caco-2 及HT-29 MTX細胞皆具有較高的黏附指數。
6. 兒童食用安全性
依據實驗結果顯示，鼠李糖乳桿菌HN001™對於新生兒及滿兩歲兒童具有良好耐受性無不良反應，攝食後不影響兒童
生長發育。
根據體外試驗的結果顯示，鼠李糖乳桿菌HN001™具有良好對抗胃酸以及膽鹽能力。
5. 良好附著腸道上皮組織能力
根據不同菌株對人體腸道上皮細胞的黏附指數之實驗結果顯示，鼠李糖乳桿菌HN001™相較於其他實驗菌株在HT-29、
Caco-2 及HT-29 MTX細胞皆具有較高的黏附指數。
6. 兒童食用安全性
依據實驗結果顯示，鼠李糖乳桿菌HN001™對於新生兒及滿兩歲兒童具有良好耐受性無不良反應，攝食後不影響兒童
生長發育。
( 二 ) 健康效益 :
-
1. 提升母親與嬰兒免疫能力
此實驗對象包含105位懷孕孕婦，於分娩前2-5周每日補充攝取HN001™直到產後，且出生之新生兒也給予HN001™直到兩歲。此實驗結果顯示HN001™有助於提升母乳中IgA及TGF-β1濃度，增強母乳中的營養價值，從而提升新生兒免疫能力。 -
2. 減緩兒童過敏性濕疹
實驗結果顯示給予新生兒補充HN001™可以顯著降低兒童過敏性濕疹發生率，相較於安慰劑組別，於出生2年內可有效降低接近50%的濕疹發病率。
-
3. 持續減輕兒童過敏現象
依據結果顯示，即使停止給予HN001™介入，也可以持續減輕兒童的皮膚過敏現象。
參考文獻:
1. Ahrné, S., Lönnermark, E., Wold, A. E., Åberg, N., Hesselmar, B., Saalman, R., ... & Adlerberth, I. (2005). Lactobacilli in the intestinal microbiota of Swedish infants. Microbes and infection, 7(11-12), 1256-1262.
2. Prasad, J., Gill, H., Smart, J., & Gopal, P. K. (1998). Selection and characterisation of Lactobacillus and Bifidobacterium strains for use as probiotics. International Dairy Journal, 8(12), 993-1002.
3. Zhou, J. S., Shu, Q., Rutherfurd, K. J., Prasad, J., Gopal, P. K., & Gill, H. S. (2000). Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria. Food and Chemical Toxicology, 38(2-3), 153-161.
4. Gopal, P. K., Prasad, J., Smart, J., & Gill, H. S. (2001). In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. International journal of food microbiology, 67(3), 207-216.
5. Dekker, J. W., Wickens, K., Black, P. N., Stanley, T. V., Mitchell, E. A., Fitzharris, P., ... & Crane, J. (2009). Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 in human infants aged 0–2 years. International Dairy Journal, 19(3), 149-154.
6. Prescott, S. L., Wickens, K., Westcott, L., Jung, W., Currie, H., Black, P. N., ... & Siebers, R. (2009). Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection. Clin Exp Allergy, 38(10):1606-1614.
7. Wickens, K., Black, P. N., Stanley, T. V., Mitchell, E., Fitzharris, P., Tannock, G. W., ... & Probiotic Study Group. (2008). A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 122(4), 788-794.
8. Wickens, K., Black, P., Stanley, T. V., Mitchell, E., Barthow, C., Fitzharris, P., ... & Crane, J. (2012). A protective effect of L actobacillus rhamnosus HN 001 against eczema in the first 2 years of life persists to age 4 years. Clinical & Experimental Allergy, 42(7), 1071-1079.
1. Ahrné, S., Lönnermark, E., Wold, A. E., Åberg, N., Hesselmar, B., Saalman, R., ... & Adlerberth, I. (2005). Lactobacilli in the intestinal microbiota of Swedish infants. Microbes and infection, 7(11-12), 1256-1262.
2. Prasad, J., Gill, H., Smart, J., & Gopal, P. K. (1998). Selection and characterisation of Lactobacillus and Bifidobacterium strains for use as probiotics. International Dairy Journal, 8(12), 993-1002.
3. Zhou, J. S., Shu, Q., Rutherfurd, K. J., Prasad, J., Gopal, P. K., & Gill, H. S. (2000). Acute oral toxicity and bacterial translocation studies on potentially probiotic strains of lactic acid bacteria. Food and Chemical Toxicology, 38(2-3), 153-161.
4. Gopal, P. K., Prasad, J., Smart, J., & Gill, H. S. (2001). In vitro adherence properties of Lactobacillus rhamnosus DR20 and Bifidobacterium lactis DR10 strains and their antagonistic activity against an enterotoxigenic Escherichia coli. International journal of food microbiology, 67(3), 207-216.
5. Dekker, J. W., Wickens, K., Black, P. N., Stanley, T. V., Mitchell, E. A., Fitzharris, P., ... & Crane, J. (2009). Safety aspects of probiotic bacterial strains Lactobacillus rhamnosus HN001 and Bifidobacterium animalis subsp. lactis HN019 in human infants aged 0–2 years. International Dairy Journal, 19(3), 149-154.
6. Prescott, S. L., Wickens, K., Westcott, L., Jung, W., Currie, H., Black, P. N., ... & Siebers, R. (2009). Supplementation with Lactobacillus rhamnosus or Bifidobacterium lactis probiotics in pregnancy increases cord blood interferon-gamma and breast milk transforming growth factor-beta and immunoglobin A detection. Clin Exp Allergy, 38(10):1606-1614.
7. Wickens, K., Black, P. N., Stanley, T. V., Mitchell, E., Fitzharris, P., Tannock, G. W., ... & Probiotic Study Group. (2008). A differential effect of 2 probiotics in the prevention of eczema and atopy: a double-blind, randomized, placebo-controlled trial. Journal of Allergy and Clinical Immunology, 122(4), 788-794.
8. Wickens, K., Black, P., Stanley, T. V., Mitchell, E., Barthow, C., Fitzharris, P., ... & Crane, J. (2012). A protective effect of L actobacillus rhamnosus HN 001 against eczema in the first 2 years of life persists to age 4 years. Clinical & Experimental Allergy, 42(7), 1071-1079.
→ 本網站提及之益生菌對人體健康效益的文章與內容、科學數據，均為益生菌本身之科學實驗數據，非我司產品宣傳。我司產品不用於診斷、預防與治療疾病。
→ 更多 Lactobacillus Rhamnosus HN001™ 益生菌決方案，請洽詢呈定企業有限公司了解更多
→ 更多 Lactobacillus Rhamnosus HN001™ 益生菌決方案，請洽詢呈定企業有限公司了解更多